Q-omics provides the consensus-scored RPL19P16 profile across patient tissues and cancer cell-line models. RPL19P16 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RPL19P16 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, RPL19P16 RNA expression shows 7,488 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight CESC, COAD, and OV as cancer lineages where RPL19P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL19P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL19P16 survival associations across molecular data types. RPL19P16 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL19P16 RNA expression–survival associations across cancer types. High RPL19P16 expression shows unfavorable associations in LIHC, OV, LUAD and STAD, but favorable associations in CESC and THCA. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for RPL19P16 RNA expression.
This table summarizes RPL19P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL19P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL19P16 shows lower tumor expression in LUAD and LUSC and higher tumor expression in COAD, KIRC, LIHC and THCA. The COAD box plot shows higher RPL19P16 RNA expression in tumor versus normal tissue (log2 FC = +0.474, t-test p < 0.001).
This table shows molecular features associated with RPL19P16 in patient tissues and cancer cell lines. In patient samples, RPL19P16 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
